Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients A Randomized Clinical Trial
신장 이식 수용자에서 상 동성 대 이종 제 3 백신 용량 4 주 후 SARS-COV-2 항체 반응의 비교 무작위 임상 시험
Randomized Controlled Trial
[키워드] 1:1
95% CI
addition
age
Analysis
antibody
Antibody Response
antibody response rate
association
BNT162b2
Characteristics
clinical
clinical trial
comparable
conducted
develop
dose
doubling
Effectiveness
end point
EudraCT
evaluated
finding
Frequency
groups
Heterologous
homologous
immune response
immunogenicity
Immunosuppression
Importance
induce
injection
injection site
interferon
interferon-γ
kidney transplant
kidney transplant recipient
kidney transplant recipients
local pain
Logistic regression
measure
mRNA
mRNA vaccine
mRNA-1273
mRNA-based
Neutralizing antibodies
neutralizing antibody
no statistically significant difference
objective
Odds ratio
participant
Patient
performed
plasma
Point
positive response
Preliminary data
randomized clinical trial
reactogenicity
recipient
Registration
Relevance
response
response rate
Result
Safe
SARS-CoV-2
SARS-CoV-2 antibodies
SARS-CoV-2 antibody
SARS-CoV-2 spike protein
SARS-CoV-2 vaccination
SARS-CoV-2 vaccine
secondary
Seroconversion
seroconverted patient
seroconverted patients
setting
significantly
single center
Spike protein
statistically significant difference
study population
systemic symptom
systemic symptoms
T-cell Response
the SARS-CoV-2
the vaccine
the vaccines
Transplant
vaccination
Vaccination strategy
Vaccine
vaccine dose
vaccine response
Vaccines
vector
Vector-based vaccine
Viral
Viral vector vaccines
virus
Week
women
[DOI] 10.1001/jamainternmed.2021.7372 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1001/jamainternmed.2021.7372 PMC 바로가기 [Article Type] Randomized Controlled Trial